Dr. Andrew Snyder (Monash University) joins the show to discuss the current biotech landscape: rising M&A and IPO activity, where clinical-stage assets are attracting buyers, and which therapeutic areas are gaining momentum (oncology, rare disease, metabolic/diabetes). He explains how AI is being deployed to speed research and data synthesis, the potential impact on drug development timelines, and why early-stage funding needs to return to replenish pipelines. They also touch on psychedelics research, recent breakthrough drugs affecting patient access, and the broader implications of drug-pricing policies on the industry. Practical advice for founders: tell a differentiated story, show a clear path to clinic, and demonstrate how quickly you can get safe patient data.